Stock Based Compensation (Tables)

9 Months Ended

Jun. 30, 2019

Stock compensation expense for the three and nine months ended June 30, 2019 and 2018 is as follows:


	Three Months Ended		Three Months Ended
	June 30, 2019		June 30, 2018
Stock Grants	$	73,000	$	78,000
Restricted Stock Grants		6,000		14,000
Option Grants		—		—
Employee Stock Purchase Plan		1,000		1,000
Subsidiary Option Grants		10,000		27,000
Total	$	90,000	$	120,000


	Nine Months Ended		Nine Months Ended
	June 30, 2019		June 30, 2018
Stock Grants	$	215,000	$	209,000
Restricted Stock Grants		29,000		40,000
Option Grants		—		17,000
Employee Stock Purchase Plan		3,000		2,000
Subsidiary Option Grants		32,000		83,000
Total	$	279,000	$	351,000

Schedule of Nonvested restricted stock units activity

A summary of restricted stock activity for the nine months ended June 30, 2019 is presented below:


Restricted Stock Activity for the Nine Months		Weighted-Average
ended June 30, 2019	Shares	Grant-Date Fair Value
Nonvested at September 30, 2018	60,000	$	1.61

Granted	—		—
Vested	(35,000)		1.68
Cancelled	—		—
Nonvested and expected to vest at June 30, 2019	25,000	$	1.50

Stock Option Grants [Member]

Schedule of Stock option grants and Subsidiary stock option grants

During the nine months ended June 30, 2019, no Dynasil stock options were granted. A summary of stock option activity for the nine months ended June 30, 2019 is presented below:


				Weighted Average
		Weighted Average		Remain
	Options	Exercise Price per		Contractual Term
	Outstanding	Share		(in Years)
Balance at September 30, 2018	160,537	$	2.01	0.93
Outstanding and exercisable at September 30, 2018	160,537	$	2.01	0.93
Granted	—		—
Exercised	—		—
Cancelled	(64,935)		2.33
Balance at June 30, 2019	95,602	$	1.80	0.59
Outstanding and exercisable at June 30, 2019	95,602	$	1.80	0.59

Subsidiary option grants [Member]

Schedule of Stock option grants and Subsidiary stock option grants

During the nine months ended June 30, 2019, no Xcede stock options were granted. A summary of Xcede stock option activity for the nine months ended June 30, 2019 is presented below:


				Weighted Average
		Weighted Average		Remain
	Options	Exercise Price per		Contractual Term
	Outstanding	Share		(in Years)
Balance at September 30, 2018	1,300,956	$	1.00	7.10
Outstanding and exercisable at September 30, 2018	1,229,685		1.00	7.11
Granted	—		—
Exercised	—		—
Cancelled	—		—
Balance at June 30, 2019	1,300,956		1.00	6.35
Outstanding and exercisable at June 30, 2019	1,283,768	$	1.00	6.35